Drug Trial Radar · NCT07523282
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Shenzhen MagicRNA Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- The First Affiliated Hospital of University of Science and Technology of China
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
Conditions
- Autoimmune Disease
- Systemic Lupus Erythematosus
- Systemic Sclerosis (SSc)
Interventions
HN2302 InjectionDrug
Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: Up to 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.